Cabot Wealth Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Cabot Wealth Management’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,981	Closed	-$244K	–	164
2021 Q4	$244K	Hold	3,981	–	–	0.03%	150
2021 Q3	$297K	Sell	3,981 -6	-0.2%	-$503	0.04%	137
2021 Q2	$369K	Sell	3,987 -319	-7%	-$27.1K	0.05%	128
2021 Q1	$382K	Buy	4,306 +13	+0.3%	+$1.29K	0.05%	121
2020 Q4	$400K	Hold	4,293	–	–	0.06%	114
2020 Q3	$274K	Hold	4,293	–	–	0.05%	122
2020 Q2	$223K	Buy	+4,293	New	+$184K	0.04%	126

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Cabot Wealth Management's ARKG Position: Q1 2022 in Review

Cabot Wealth Management sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2022, closing a stake of 3,981 shares — an estimated $244K sold.

Cabot Wealth Management first reported a position in ARKG in Q2 2020 and held it in 7 quarters. The position peaked at $400K in Q4 2020. 387 funds tracked by Wall St. Rank hold ARKG as of Q1 2022.

Cabot Wealth Management reported no remaining ARK Genomic Revolution ETF position as of Q1 2022 after selling out during the quarter.
Cabot Wealth Management sold 3,981 ARK Genomic Revolution ETF shares in Q1 2022, an estimated $244K.
Cabot Wealth Management first reported a position in ARK Genomic Revolution ETF in Q2 2020 and held it in 7 quarters.
Cabot Wealth Management's ARK Genomic Revolution ETF position peaked at $400K in Q4 2020.
387 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2022.

Based on Cabot Wealth Management's 13F filing for Q1 2022, filed 14 Apr 2022.